Dr. Every is a cardiologist who has been with Frazier Healthcare since 1999, became a partner in 2001 and General Partner in 2005. Dr. Every is a member of Frazier's Growth Equity and Biopharma Venture teams. Exited investments include Biostent (acquired by Abbott), Rigel (NASDAQ) and Flowcardia (acquired by C.R. Bard),  BARRX, Inc. (acquired by Covidien) and Ascension Orthopedics (acquired by Integra Lifesciences). Dr. Every currently serves on the boards of Calibra Medical, Cardiac Dimensions, Correct Care Solutions, DSI, Silvergate and PowerVision.

Prior to joining Frazier Healthcare, Dr. Every was an associate professor of medicine and the director of the Cardiovascular Outcomes Research Center (CORC) at the University of Washington, where he performed multiple studies evaluating the costs and outcomes of new procedures and pharmaceutical agents. His findings have been published in more than 75 scientific articles, including The New England Journal of Medicine, JAMA and The Lancet. Dr. Every earned an M.D. from Emory University School of Medicine and a master of public health (M.P.H.) degree from the University of Washington School of Public Health, and he is board certified in internal medicine and cardiovascular medicine.

Feel free to contact him at nathan@frazierhealthcare.com